FDA won't extend exclusivity on GSK-marketed drug

Pozen said FDA will not grant a pediatric exclusivity to its Treximet migraine drug, a decision that can open up generic competition. Marketed by Pozen's U.S. partner GlaxoSmithKline, Treximet's exclusivity is set to expire April 15. Report